Epic

Epic Bio is a clinical-stage biotechnology company pioneering a new class of genetic medicines through epigenetic engineering. The company utilizes its proprietary Gene Expression Modulation System (GEMS) platform to precisely turn genes on or off without permanently altering the underlying DNA sequence, potentially offering a safer and more tunable alternative to traditional CRISPR genome editing. Their lead program, EPI-321, is targeting facioscapulohumeral muscular dystrophy (FSHD) and has received IND clearance. Epic Bio's pipeline also includes preclinical programs in liver disease, cardiovascular health, and neurodegeneration, leveraging ultra-small DNA-binding proteins to enable efficient delivery via viral vectors.